ArticleScientific reports2026
Conserved genetic and antigenic profiles of Pf12 and Pf41 in asymptomatic Plasmodium falciparum carriers in Tanzania.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Plasmodium falciparum remains a major cause of mortality in malaria-endemic regions, and strain-specific immunity limits vaccine efficacy. The 6-cysteine proteins Pf12 and Pf41 are proposed blood-stage vaccine candidates, yet their diversity and antigenicity in asymptomatic carriers are poorly defined. Genetic variation and natural selection pressure were analyzed in 172 P. falciparum isolates from asymptomatic individuals in Tanzania. Genomic DNA extracted from dried blood spots was amplified by PCR and subsequently sequenced to evaluate genetic diversity. IgG responses to recombinant Pf12 and Pf41 were quantified using a protein microarray. Statistical analyses included Spearman's correlation to assess antibody associations and unpaired t-tests to compare IgG levels between parasite-positive and parasite-negative individuals. Both genes exhibited low nucleotide diversity (pf12 π = 0.00042 ± 0.00007; pf41 π = 0.00061 ± 0.00004) and negative Tajima's D values suggest that both genes are under selective constraints, consistent with purifying or directional selection. Neutrality test indicated an excess of rare variants consistent with recent population expansion. Haplotype network showed limited regional differentiation, supporting strong conservation. Pf12 and Pf41 elicited high IgG seropositivity (97.7% and 98.3%), with strongly correlated antibody levels (ρ = 0.721, p < 0.001). A predominant Pf41 substitution, S232R (47.8%), and rare Asn/His variants (0.6%) were detected. Overall, both proteins display limited polymorphism and robust IgG recognition, features consistent with exposure-driven immunity. These findings highlight conserved merozoite antigens that warrant further investigations for their biological relevance and vaccine potential, particularly to determine their functional role in protective immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.